Research and Collaboration Arrangements - CFF - Additional Information (Details) - CFF Agreement - Cystic Fibrosis Foundation	1 Months Ended		6 Months Ended	12 Months Ended
	Aug. 31, 2023 USD ($)	Sep. 30, 2016 USD ($) Installment	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement total amount of award	$ 6,300,000	$ 3,500,000
Collaborative arrangement achieved milestones			$ 1,800,000	$ 1,700,000
Expected payments multiples to equal actual award received		6
Number of installments to pay actual award | Installment		3
Actual award payment period upon first commercial sale of product		4 years
Continuous period where the Company ceases to develop or commercialize any product		180 days
Collaborative arrangements special term		If at any time prior to the first commercial sale of a product developed as a result of the CFF Agreement, the Company ceases to use commercially reasonable efforts to develop or commercialize any product under the CFF Agreement for a continuous period of 180 consecutive days and fails to present a reasonable plan to resume commercially reasonable efforts, the Company will grant to CFF an irrevocable, exclusive worldwide interruption license under all of the Company’s interest in the research plan technology to exploit such product. Any third-party license granted by the Company shall be subject to such interruption license.
Deferred revenue			1,300,000	1,200,000
Accounts receivable			0	0
Aggregate amount of transaction price allocated to remaining performance obligation			$ 1,300,000	$ 1,200,000
Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future sales-based milestone payments multiples		3
Royalties multiples on actual award received		6